STOCK TITAN

Ligand Pharmaceuticals Incorporated - LGND STOCK NEWS

Welcome to our dedicated page for Ligand Pharmaceuticals Incorporated news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharmaceuticals Incorporated stock.

Ligand Pharmaceuticals Inc. (symbol: LGND) is a prominent biopharmaceutical company committed to advancing healthcare through innovative technologies and strategic partnerships. The company focuses on developing and acquiring assets that support the creation and commercialization of medicine. Ligand operates with a streamlined cost structure to maximize cash flow and enhance shareholder returns.

The company’s revenue is derived from three primary sources: royalties from commercialized products, license and milestone payments, and the sale of its proprietary Captisol material. Captisol is a chemically modified cyclodextrin that enhances the solubility and stability of drugs.

Ligand has a diverse portfolio of commercial and near-term revenue-generating assets. Its business model includes drug discovery, early-stage drug development, product reformulation, and alliances with other pharmaceutical and biotechnology companies. These partnerships and license agreements are crucial for the company’s long-term financial growth.

Recently, Ligand has made significant strides in its ongoing projects and collaborations. The company continues to build a robust pipeline with an emphasis on innovation and operational efficiency. Investors and stakeholders can expect regular updates on the company’s performance, new agreements, and advancements in drug development.

With a commitment to delivering meaningful returns and improving global health outcomes, Ligand Pharmaceuticals remains a key player in the biopharmaceutical industry. Stay informed about the latest news and developments by following Ligand's journey and updates.

Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) will acquire APEIRON Biologics AG for $100 million in cash, gaining royalty rights to QARZIBA®, an oncology drug for high-risk neuroblastoma marketed in 35 countries.

This acquisition will immediately increase Ligand's EPS by $1.00 annually and increase 2024 adjusted EPS guidance by 17% to $5.00-$5.50. Additional consideration up to $28 million may be paid to APEIRON based on future QARZIBA royalties by 2030 or 2034.

Ligand's 2024 revenue guidance is raised to $140 million-$157 million, and royalties expected to range from $100 million-$105 million. The transaction, approved by both companies' boards, is expected to close in July 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
-
Rhea-AI Summary

Ligand Pharmaceuticals announced that its partner, Verona Pharma, received FDA approval for Ohtuvayre™ (ensifentrine), the first inhaled novel mechanism of action drug for COPD maintenance treatment in over 20 years. Ligand will receive a $5.8 million milestone payment and an additional $13.8 million upon commercial launch in Q3 2024. Ligand is also entitled to a low single-digit royalty on worldwide net sales of Ohtuvayre.

This marks Ligand's second FDA approval within a fortnight and the eighth since 2023. Ohtuvayre targets the multi-billion-dollar COPD market in the U.S. and is expected to bolster Ligand’s growth. The drug combines bronchodilator and non-steroidal anti-inflammatory effects, delivered via a standard jet nebulizer, enhancing ease of use for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.8%
Tags
-
Rhea-AI Summary

Ligand Pharmaceuticals announced that its collaborator Merck has received FDA approval for CAPVAXIVE™, a 21-valent pneumococcal conjugate vaccine for adults. This marks the sixth FDA-approved product utilizing Ligand's Pfenex Expression Technology® platform. Merck's approval triggers a $2 million milestone payment to Ligand, which is also entitled to royalties on global net sales. CAPVAXIVE, previously known as V116, is intended to prevent invasive pneumococcal disease and pneumonia. The PeliCRM197® carrier protein, enhancing antigen immunogenicity, is a key component of this vaccine. Ligand continues to collect commercial royalties on products developed with its technology, including CAPVAXIVE.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.12%
Tags
Rhea-AI Summary

Ligand Pharmaceuticals (Nasdaq: LGND) announced the participation of its CEO, Todd Davis, and CFO, Tavo Espinoza, in two upcoming investor conferences. The company will attend the Craig-Hallum Institutional Investor Conference in Minneapolis on May 29, 2024, where management will hold one-on-one meetings with investors. Additionally, Ligand will present at the Goldman Sachs Global Healthcare Conference in Miami on June 12, 2024, at 4:00 p.m. ET, and will also be available for one-on-one meetings. Interested investors should contact their respective institutional equity sales representatives at Craig-Hallum or Goldman Sachs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
conferences
-
Rhea-AI Summary

Ligand Pharmaceuticals and Agenus have entered into a $100 million royalty financing agreement to support Agenus' key development initiatives in the BOT/BAL clinical development program. Ligand will pay $75 million initially and can invest an additional $25 million. They will receive royalties and milestone payments on six Agenus-partnered programs and future global net sales generated by BOT/BAL. Agenus can syndicate up to $125 million, with potential total capital infusion of $200 million. The partnership aims to advance transformative cancer treatments, including the BOT/BAL regimen.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
none
-
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) will report its first quarter 2024 financial results on May 7, 2024, after the close of the U.S. financial markets. A conference call will be held at 4:30 p.m. Eastern Time to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences earnings
Rhea-AI Summary
Ligand Pharmaceuticals Incorporated (LGND) partners with the University of Minnesota and CURx Pharmaceuticals to present new data on Captisol-enabled™ Topiramate Injection as a potential substitute for oral topiramate in treating neurological conditions like epilepsy. The IV formulation of topiramate simplifies replacement therapy, allowing for proper dosing in various clinical scenarios. Ligand holds the license for IV topiramate and is entitled to milestone payments and royalties on global sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
none
-
Rhea-AI Summary
Ligand Pharmaceuticals announces the launch of Pelthos Therapeutics and the appointment of Scott Plesha as CEO. Pelthos aims to commercialize ZELSUVMI, a topical gel for molluscum contagiosum, expected to be available in late 2024. The product received FDA approval and is developed using Pelthos' proprietary technology platform. Ligand acquired the rights to ZELSUVMI from Novan, Inc. in 2023. Scott Plesha brings over 30 years of pharmaceutical industry experience to the role, with a successful track record in building commercial organizations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.08%
Tags
none
-
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) CEO and CFO to participate in a fireside chat at the Barclays Healthcare Conference. The event is on March 14, 2024, in Miami.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
conferences
Rhea-AI Summary
Ligand Pharmaceuticals (LGND) granted a non-qualified stock option award to an employee for 15,100 shares of common stock under the Inducement Plan. The options have an exercise price of $78.70 per share, a ten-year term, and will vest over four years. This award aims to attract and retain talent within the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.07%
Tags
none

FAQ

What does Ligand Pharmaceuticals Inc. do?

Ligand Pharmaceuticals Inc. develops and acquires technologies that aid in creating medicine, focusing on drug discovery, early-stage drug development, product reformulation, and partnerships.

What are the primary sources of revenue for Ligand?

Ligand’s revenue primarily comes from royalties from commercialized products, license and milestone payments, and the sale of its proprietary Captisol material.

What is Captisol?

Captisol is a modified cyclodextrin used to improve the solubility and stability of drugs, contributing significantly to Ligand's revenue stream.

How does Ligand aim to maximize shareholder returns?

Ligand maximizes shareholder returns by operating on a lean cost structure, focusing on commercial and near-term revenue-generating assets to enhance cash flow.

What is Ligand’s business model?

Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and forming strategic partnerships with pharmaceutical and biotechnology companies.

Who are Ligand’s partners?

Ligand has partnerships and license agreements with various pharmaceutical and biotechnology companies, leveraging their collaborations for mutual growth.

What recent achievements has Ligand made?

Ligand has made significant advancements in its projects and collaborations, building a strong pipeline centered on innovation and operational efficiency.

How does Ligand maintain its operations cost-effectively?

Ligand maintains cost-effective operations by using a streamlined cost structure that enhances cash flow and focuses on strategic investments.

What can investors expect from Ligand in the future?

Investors can expect continuous updates on the company’s performance, new agreements, and progress in drug development, contributing to long-term financial growth.

How can I stay informed about Ligand's latest news?

You can stay informed about Ligand’s latest news and developments by following their updates and announcements regularly.

Ligand Pharmaceuticals Incorporated

Nasdaq:LGND

LGND Rankings

LGND Stock Data

1.74B
17.96M
2.35%
95.52%
5.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO